Publikationen, an denen er mitarbeitet CARLOS JAVIER ANGUITA VELASCO (33)

2024

  1. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy

    Blood transfusion = Trasfusione del sangue, Vol. 22, Núm. 3, pp. 239-245

  2. Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients

    Transplantation and Cellular Therapy, Vol. 30, Núm. 3, pp. 306.e1-306.e12

  3. Identification of predictive models including polymorphisms in cytokines genes and clinical variables associated with post-transplant complications after identical HLA-allogeneic stem cell transplantation

    Frontiers in Immunology, Vol. 15

2023

  1. Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide

    Annals of Hematology, Vol. 102, Núm. 6, pp. 1561-1567

  2. Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy

    Frontiers in immunology, Vol. 14, pp. 1165759

2022

  1. Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation

    Frontiers in immunology, Vol. 13, pp. 1002959

  2. FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 16

2021

  1. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  2. Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  3. Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant

    Frontiers in Immunology, Vol. 12

  4. Next generation cytogenetics in myeloid hematological neoplasms: Detection of cnvs and translocations

    Cancers, Vol. 13, Núm. 12

  5. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation

    Annals of Hematology, Vol. 100, Núm. 2, pp. 541-553

2020

  1. Autologous stem cell transplantation for lymphoma in HIV+ patients: higher rate of infections compared with non-HIV lymphoma

    Bone Marrow Transplantation, Vol. 55, Núm. 9, pp. 1716-1725

  2. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide

    Hematological Oncology, Vol. 38, Núm. 4, pp. 597-603

  3. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 11, pp. 2089-2097

2019

  1. Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders

    AIDS, Vol. 33, Núm. 9, pp. 1441-1447

  2. Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center

    Journal of Clinical Apheresis, Vol. 34, Núm. 4, pp. 373-380

  3. Mononuclear cell collection for extracorporeal photopheresis by using the “off-line” system: A comparative study between COBE Spectra and Spectra Optia devices

    Journal of Clinical Apheresis, Vol. 34, Núm. 4, pp. 359-366

  4. Next-generation sequencing improves diagnosis, prognosis and clinical management of myeloid neoplasms

    Cancers, Vol. 11, Núm. 9

  5. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation

    Blood Advances, Vol. 3, Núm. 21, pp. 3351-3359